Jochen Hefner - Concepedia

Author

Jochen Hefner

University of Würzburg

Also Known As

Hefner J, Hefner, Jochen, J Hefner, J. Hefner, J.G. Hefner, Jochen Hefner

Publications

300

Citations

H-Index

Concepts

All Affiliations

University of Würzburg University Hospital Cologne

About

Jochen Hefner is an author at University of Würzburg specializing in medicine, hematology, and toxicology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	114
2	Biochemistry	1	1	43
3	Classical Hematology	1	1	53
4	Immunology	1	1	18
5	Pharmacology	1	1	43

Jochen Hefner

Publications

181

Citations

H-Index

Page 1

	Year	Citations
High prevalence of distress in patients after allogeneic hematopoietic SCT: Fear of progression is associated with a younger age Jochen Hefner, Markus Kapp, K Drebinger, Bone Marrow Transplantation Bone Marrow FailurePsychiatryPediatric HematologyHematologyAllogeneic Hematopoietic Sct	2014	53
The in vivo biotransformation of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in the rat J.C. Ramsey, Jochen Hefner, R.J. Karbowski, Toxicology and Applied Pharmacology BiochemistryMedicineBioanalysisToxicologyEcotoxicology	1982	43
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy Sophia Danhof, Susanne Strifler, Dorothea Hose, Journal of Cancer Research and Clinical Oncology Hematological MalignancyMedicineMalignant Blood DisorderBiological CharacteristicsHematology	2018	18
Recurrent Tako-Tsubo cardiomyopathy (TTC) in a pre-menopausal woman: late sequelae of a traumatic event? Jochen Hefner, Herbert Csef, Stefan Frantz, BMC Cardiovascular Disorders	2015	16
Spirituality and Cancer Herbert Csef, Jochen Hefner	2007	14
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers Dorothea Hose, Martin Schreder, Jochen Hefner, Journal of Cancer Research and Clinical Oncology	2020	14
New insights into frequency and contents of fear of cancer progression/recurrence (FOP/FCR) in outpatients with colorectal carcinoma (CRC) receiving oral capecitabine: a pilot study at a comprehensive cancer center Jochen Hefner, Sara Berberich, Elena Lanvers, Patient Preference and Adherence	2017	12
Patient&ndash;doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center Jochen Hefner, Sara Berberich, Elena Lanvers, Patient Preference and Adherence	2018	11

Page 1